FDA Extends Orladeyo Pellets to Teens and Adults With HAE

Orladeyo oral pelletsWhat to know

30-second read

For Allergy & Immunology · Pediatrics

Who

Patients 12 and older with hereditary angioedema (HAE) who have genuine difficulty swallowing capsules on a chronic, once-daily regimen.

What’s new

FDA extended the 150mg oral-pellet formulation — approved only for ages 2 to <12 since Dec 2025 — to the 12-and-older population already eligible for the capsule.

Evidence

Approved on manufacturing (CMC) and safety/tolerability data vs the capsule — no new efficacy trial. Efficacy rests on the capsule's APeX-2 data.

Big advantage

A labeled alternative to off-label capsule-opening and food-mixing, which carries no FDA-reviewed safety data, for patients who cannot reliably swallow the capsule.

Key consideration

This is a formulation and access change, not a new efficacy signal — no reason to switch a patient already stable and adherent on the capsule.

Availability

Approved 21 October 2026. Both formulations ship through CareMed, BioCryst's sole-source specialty pharmacy since Q3 2026 — a new intake step for prescribers.

Practice impactConsider for selected patients

Useful for the minority of adolescents and adults who genuinely cannot swallow the capsule reliably — not a reason to revisit a regimen that is already working.

Read the full physician analysis

Full analysis · 6 min readBioCryst, FDA approval, 21 Oct 2026 · Orladeyo prescribing information · APeX-2 trial

FDA approved a supplemental New Drug Application on 21 October 2026 extending BioCryst Pharmaceuticals' 150mg oral-pellet formulation of Orladeyo (berotralstat) to patients 12 years and older, giving adolescents and adults with hereditary angioedema (HAE) who struggle to swallow capsules an FDA-labeled alternative dosage form. It is not a new drug, a new indication, or new efficacy data: Orladeyo capsules have been approved for this age group since December 2020, and the pellet itself was already approved for children as young as two in December 2025. What changed is who the pellet is labeled for.

What actually changed, and what didn’t

BioCryst's own announcement describes the basis for this approval plainly: chemistry, manufacturing and controls (CMC) information, plus data demonstrating the pellet's safety and tolerability compared with the capsule — not a head-to-head efficacy trial and not a formal pharmacokinetic bioequivalence study reported in public materials to date. That distinction matters clinically. The capsule's effectiveness at preventing HAE attacks is unchanged and well established; this action simply makes an already-approved delivery format available to a population that previously had no FDA-reviewed alternative to swallowing the capsule whole.

Why a pellet exists for a drug most patients swallow fine

HAE prophylaxis with berotralstat is a lifelong, once-daily regimen, not an as-needed treatment, which makes swallowing ability a real adherence variable over years rather than a one-time inconvenience. The pellet formulation was developed first for young children, who often cannot swallow a capsule at all; this extension recognizes that some adolescents and adults share the same limitation — dysphagia from an unrelated condition, a difficult transition from pediatric to adult dosing, or a long-standing pattern of opening the capsule and mixing its contents with food, an off-label workaround with no FDA-reviewed data behind it. The pellet replaces that workaround with a labeled option rather than eliminating the capsule as the default.

What the efficacy evidence still rests on: APeX-2 (capsule)

1.31 vs 2.35HAE attacks per month at 24 weeks, berotralstat 150mg once daily vs placebo (p<0.001)

1.65 vs 2.35Attacks per month, berotralstat 110mg vs placebo (p=0.024)

121Adults randomized in APeX-2; 120 received at least one dose

0Drug-related serious adverse events reported through 24 weeks

APeX-2 tested the capsule, not the pellet, and predates this approval. No new efficacy trial supports the pellet specifically in patients 12 and older; cited here because it remains the evidence base prescribers are relying on.

Where berotralstat sits against the injectable option

Berotralstat is not the only long-term HAE prophylaxis option, and the pellet extension does not change where it sits competitively. No head-to-head trial has compared berotralstat with lanadelumab (Takhzyro), the injectable plasma kallikrein inhibitor given by subcutaneous injection every two to four weeks; an indirect network meta-analysis of the Phase 3 programs found lanadelumab associated with significantly greater attack-rate reduction than either berotralstat dose. The two drugs' adverse-event profiles also differ in kind rather than severity — pharmacovigilance reporting associates berotralstat predominantly with gastrointestinal events (abdominal pain, vomiting, diarrhea) and lanadelumab predominantly with injection-site reactions and infections — which is one reason an oral option remains attractive for patients who decline or cannot tolerate routine injections, independent of which drug controls attacks more completely on average. None of that calculus changes with this approval; it only broadens who can take the oral option in pellet form.

What changes in practice

• Patient selection. Reserve the pellet for patients 12 and older with a documented, genuine difficulty swallowing capsules reliably — not general preference; a stable, adherent patient on the capsule has no clinical reason to switch.
• The pediatric-to-adult transition. Adolescents aging out of the under-12 pellet population, or caregivers managing that transition, now have continuity of formulation into adulthood rather than a forced switch to capsules at 12.
• Specialty-pharmacy logistics. Both Orladeyo formulations route through CareMed, BioCryst's sole-source specialty pharmacy since the third quarter of 2026; build that into new-patient onboarding rather than assuming a standard retail fill.
• Confirm the updated label before switching anyone. Exact dosing equivalence, storage and administration instructions for the pellet in this age group belong in FDA's official prescribing information once fully updated — confirm against that primary document, not secondary coverage, before changing a stable patient's regimen.
• Prior authorization. Expect payers to treat a capsule-to-pellet switch as a formulary and medical-necessity question, with documented swallowing difficulty likely to matter for approval.

The honest summary is that this approval does not change how well Orladeyo prevents HAE attacks or who is a candidate for the drug itself — it changes how a defined minority of patients 12 and older can take it. For a practice, the work is identifying the small number of patients for whom swallowing has genuinely been a barrier to adherence, not rewriting management for the HAE panel generally.

Orladeyo's formulations, in order

1. Dec 3, 2020

   Capsule approved

   FDA approves Orladeyo capsules for HAE prophylaxis in patients 12 and older; BioCryst's first commercial product.

2. Dec 12, 2025

   Pellet approved for young children

   FDA approves the 150mg oral-pellet formulation for ages 2 to under 12, based on the APeX-P pharmacokinetic and safety study.

3. 21 Oct 2026

   Pellet extended to 12 and older

   FDA approves the sNDA extending the pellet formulation to the population already eligible for the capsule.

4. Ahead

   Updated full label

   Complete dosing-equivalence and administration detail for the pellet in patients 12 and older awaits FDA's published prescribing information.

Frequently asked questions

Is this a new drug, a new indication, or new efficacy data?

None of those. Orladeyo capsules have been approved for HAE prophylaxis in patients 12 and older since December 2020, and the 150mg oral-pellet formulation was already approved in December 2025 for children ages 2 to under 12. This action extends the existing pellet formulation's approved age range upward, to patients who could already take the capsule. BioCryst's approval rested on manufacturing (CMC) data and a safety and tolerability comparison between the pellet and the capsule — not a new efficacy trial.

Does the pellet work as well as the capsule at preventing HAE attacks?

There is no new efficacy trial comparing them in patients 12 and older. The drug's efficacy evidence remains the capsule's APeX-2 trial: berotralstat 150mg once daily cut the monthly HAE attack rate to 1.31 from 2.35 on placebo (p<0.001). Public reporting on this approval does not establish a formal bioequivalence or exposure-matching study between pellet and capsule in this age group; confirm dosing equivalence against the updated label once published.

Who should actually be considered for the pellet instead of the capsule?

Patients 12 and older with genuine difficulty swallowing capsules reliably on a chronic, once-daily regimen — not general preference. A patient stable and adherent on the capsule has no reason to switch; this closes an off-label gap where some patients or caregivers were opening capsules and mixing contents with food, a workaround with no FDA-reviewed safety data behind it.

How is Orladeyo distributed, and does that change with this approval?

BioCryst named CareMed as its new sole-source specialty pharmacy for Orladeyo shipments starting in the third quarter of 2026; pediatric pellet prescriptions were already routing through CareMed, and patients 12 and older were expected to transition during that period. Prescribers starting a new patient on either formulation should expect a single specialty-pharmacy intake process rather than a standard retail fill.